Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques

Vaccine

Volumn 31, Issue 52, 2013, Pages 6216-6224

  Vanloubbeeck, Yannick ^a   Pichyangkul, Sathit ^b   Bayat, Babak ^a   Yongvanitchit, Kosol ^b   Bennett, Jason W ^c   Sattabongkot, Jetsumon ^b   Schaecher, Kurt ^b   Ockenhouse, Christian F ^c   Cohen, Joe ^a   Yadava, Anjali ^c   Donner, Marie Noëlle ^a   Garzé, Virginie ^a   Ska, Michael ^a   Ajhir, Nora ^a   Marchand, Martine ^a   Ware, Lisa A ^c   Hall, Cysha ^c  

^a GSK   (Belgium)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

AS01; CSV S,S; Immune response; Malaria; Plasmodium vivax; VMP001

Indexed keywords

3 O DESACYL 4 MONOPHOSPHORYL LIPID A; AS 01; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MALARIA VACCINE; RECOMBINANT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIVAX MALARIA PROTEIN 1; VIVAX MALARIA PROTEIN 1 HEPATITS B SURFACE ANTIGEN FUSION PROTEIN; VMP 001;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESCHERICHIA COLI; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY; SACCHAROMYCES CEREVISIAE;

AS01; BOVINE SERUM ALBUMIN; BSA; CIRCUMSPOROZOITE; CS; CSV; CSV-S,S; HBSAG; HEPATITIS B SURFACE ANTIGEN; IFA; IMMUNE RESPONSE; IMMUNOFLUORESCENCE ASSAY; MALARIA; P.VIVAX CIRCUMSPOROZOITE PROTEIN; PBMC; PERIPHERAL BLOOD MONONUCLEAR CELLS; PLASMODIUM VIVAX; VMP001;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; ESCHERICHIA COLI; GENE EXPRESSION; MACACA MULATTA; MALARIA VACCINES; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; SACCHAROMYCES CEREVISIAE; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84888427814     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.041     Document Type: Article

References (43)

1. Roll Back Malaria Global malaria action plan 2008, Roll Back Malaria, Geneva, http://rbm.who.int/gmap/gmap.pdf.
2. Tanner M., de Savigny D. Malaria eradication back on the table. Bull World Health Organ 2008, 86(2):82. http://www.who.int/bulletin/volumes/86/2/07-050633/en/.
3. Mueller I., Galinski M.R., Baird J.K., Carlton J.M., Kochar D.K., Alonso P.L., et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 2009, 9(9):555-566.
4. Murray C.J.L., Rosenfeld L.C., Lim S.S., Andrews K.G., Foreman K.J., Haring D., et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012, 379(9814):413-431.
5. Price R.N., Tjitra E., Guerra C.A., Yeung S., White N.J., Anstey N.M. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007, 77(6 Suppl):79-87.
6. World Health Organization. World malaria report. 2010. http://www.who.int/malaria/world_malaria_report_2010/worldmalariareport2010.pdf.
7. Wells T.N.C., Burrows J.N., Baird J.K. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol 2010, 26(3):145-151.
8. Brown G.V., Moorthy V.S., Reed Z., Mendis K., Arévalo-Herrera M., Alonso P. Priorities in research and development of vaccines against Plasmodium vivax malaria. Vaccine 2009, 27(52):7228-7235.
9. World Health Organization. Tables of malaria vaccine projects globally. 2012. http://www.who.int/vaccine_research/links/Rainbow/en/index.html.
10. Charoenvit Y., Mellouk S., Cole C., Bechara R., Leef M.F., Sedegah M., et al. Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J Immunol 1991, 146(3):1020-1025.
11. Kebaier C., Voza T., Vanderberg J. Kinetics of mosquito-injected Plasmodium sporozoites in mice: fewer sporozoites are injected into sporozoite-immunized mice. PLoS Pathog 2009, 5(4):e1000399.
12. Potocnjak P., Yoshida N., Nussenzweig R.S., Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med 1980, 151(6):1504-1513.
13. Tam J.P., Clavijo P., Lu Y.-A., Nussenzweig V., Nussenzweig R., Zavala F. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J Exp Med 1990, 171(1):299-306.
14. Zavala F., Tam J.P., Barr P.J., Romero P.J., Ley V., Nussenzweig R.S., et al. Synthetic peptide vaccine confers protection against murine malaria. J Exp Med 1987, 166(5):1591-1596.
15. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200(3):337-346.
16. McCarthy V.C., Clyde D.F. Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. Exp Parasitol 1977, 41(1):167-171.
17. Charoenvit Y., Collins W.E., Jones T.R., Millet P., Yuan L., Campbell G.H., et al. Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science 1991, 251(4994):668-671.
18. Yang C., Collins W.E., Xiao L., Saekhou A.M., Reed R.C., Nelson C.O., et al. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin. Vaccine 1997, 15(4):377-386.
19. Yadava A., Sattabongkot J., Washington M.A., Ware L.A., Majam V., Zheng H., et al. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun 2007, 75(3):1177-1185.
20. Bell B.A., Wood J.F., Bansal R., Ragab H., Cargo J., Washington M.A., et al. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax. Vaccine 2009, 27(9):1448-1453.
21. Lumsden J.M., Nurmukhambetova S., Klein J.H., Sattabongkot J., Bennett J.W., Bertholet S., et al. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice. Vaccine 2012, 30(22):3311-3319.
22. fh cells and promote germinal center induction. Proc Natl Acad Sci U S A 2012, 109(4):1080-1085.
23. Moon J.J., Suh H., Polhemus M.E., Ockenhouse C.F., Yadava A., Irvine D.J. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS ONE 2012, 7(2):e31472.
24. Lumsden J.M., Pichyangkul S., Srichairatanakul U., Yongvanitchit K., Limsalakpetch A., Nurmukhambetova S., et al. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect Immun 2011, 79(9):3492-3500.
25. Bramwell V.W., Perrie Y. Particulate delivery systems for vaccines: what can we expect?. J Pharm Pharmacol 2006, 58(6):717-728.
26. Ballou W.R. The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol 2009, 31(9):492-500.
27. Jacobs E., Rutgers T., Voet P., Dewerchin M., Cabezon T., de Wilde M. Simultaneous synthesis and assembly of various hepatitis B surface proteins in Saccharomyces cerevisiae. Gene 1989, 80(2):279-291.
28. Garçon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems. Expert Rev Vaccines 2011, 10(4):471-486.
29. Institute for Laboratory Animal Research Guide for the care and use of laboratory animals 1996, The National Academy Press, Washington, DC.
30. Hollingdale M.R., Collins W.E., Campbell C.C. In vitro culture of exoerythrocytic parasites of the North Korean strain of Plasmodium vivax in hepatoma cells. Am J Trop Med Hyg 1986, 35(2):275-276.
31. Vichchathorn P., Jenwithisuk R., Leelaudomlipi S., Tungpradabkul S., Hongeng S., Cui L., et al. Induction of specific immune responses against the Plasmodium vivax liver-stage via in vitro activation by dendritic cells. Parasitol Int 2006, 55(3):187-193.
32. Jordán-Villegas A., Bonelo Perdomo A., Epstein J.E., López J., Castellanos A., Manzano M.R., et al. Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites. Am J Trop Med Hyg 2011, 84(2 Suppl):43-50.
33. Herrera S., Bonelo A., Perlaza B.L., Fernández O.L., Victoria L., Lenis A.M., et al. Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 2005, 73(5 Suppl):3-9.
34. Herrera S., Fernández O.L., Vera O., Cárdenas W., Ramírez O., Palacios R., et al. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am J Trop Med Hyg 2011, 84(2 Suppl):12-20.
35. Yadava A., Nurmukhambetova S., Pichugin A.V., Lumsden J.M. Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria. J Infect Dis 2012, 205(9):1456-1463.
36. Butler N.S., Schmidt N.W., Harty J.T. Differential effector pathways regulate memory CD8 T cell immunity against Plasmodium berghei versus P. yoelii sporozoites. J Immunol 2010, 184(5):2528-2538.
37. Depinay N., Franetich J.-F., Grüner A.C., Mauduit M., Chavatte J.-M., Luty A.J.F., et al. Inhibitory effect of TNF-α on malaria pre-erythrocytic stage development: influence of host hepatocyte/parasite combinations. PLoS ONE 2011, 6(3):e17464.
38. Doolan D.L., Hoffman S.L. The complexity of protective immunity against liver-stage malaria. J Immunol 2000, 165(3):1453-1462.
39. Lalvani A., Moris P., Voss G., Pathan A.A., Kester K.E., Brookes R., et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 1999, 180(5):1656-1664.
40. + T cells. PLoS ONE 2011, 6(7):e20775.
41. Olotu A., Moris P., Mwacharo J., Vekemans J., Kimani D., Janssens M., et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PLoS ONE 2011, 6(10):e25786.
42. Reece W.H.H., Pinder M., Gothard P.K., Milligan P., Bojang K., Doherty T., et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 2004, 10(4):406-410.
43. + T cells producing IFN-γ. J Immunol 2003, 171(12):6961-6967.